Join the Adderall group to help and get support from people like you.
Adderall News
FDA Will Now Require Labeling of ADHD Medication to Indicate Weight Loss Risk
WEDNESDAY, July 2, 2025 – The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications, including certain...
ADHD Medications Remain Linked to Lower Risk for Real-World Adverse Outcomes
WEDNESDAY, July 2, 2025 – Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of these associations...
FDA Medwatch Alert: FDA Requires Expanded Labeling About Weight Loss Risk in Patients Younger Than 6 Years Taking Extended-Release Stimulants for ADHD
FDA Drug Safety Communication - June 30, 2025 What safety concern is FDA announcing?The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated...
Prescribing ADHD Meds by Telehealth Does Not Alter Risk for Substance Use Disorder Overall
TUESDAY, June 17, 2025 – Receipt of a stimulant prescription for attention-deficit/hyperactivity disorder (ADHD) via telehealth is not associated with an increased risk for substance use disorder...
ADHD Stimulants Can Be Safely Prescribed Via Telehealth, Study Argues
MONDAY, June 16, 2025 — People with ADHD might be prescribed their meds remotely without increasing their risk of addiction, a new study says. Experts have worried that prescribing stimulants like A...
Stimulant Dispensing to Children Decreased After Start of Pandemic, During Shortage
MONDAY, Jan. 27, 2025 – Stimulant dispensing to children aged 5 to 17 years decreased after the start of the COVID-19 pandemic and during a shortage of immediate-release mixed amphetamine salts in...
Adderall Shortage Sparks Scramble for ADHD Alternatives
MONDAY, Jan. 27, 2025 – Adderall shortages have prompted doctors to switch kids with attention-deficit/hyperactivity disorder (ADHD) to other forms of stimulant medication. Adderall prescription...
About 6% of U.S. Adults Have ADHD, Drug Shortages Are Affecting Treatment
THURSDAY, Oct. 10, 2024 – More than 15.5 million U.S. adults have been diagnosed with ADHD, and nearly three-quarters of those taking medication to treat it say drug shortages are hampering their...
Rx Amphetamine Use Linked to Increased Odds of Psychosis, Mania
TUESDAY, Sept. 17, 2024 – Past-month prescription amphetamine use is associated with increased odds of psychosis and mania, with increased odds for high doses (>30 mg dextroamphetamine equivalents),...
High Doses of ADHD Meds Could Trigger Psychosis
THURSDAY, Sept. 12, 2024 – Prescriptions for amphetamine stimulants to treat ADHD have increased significantly in recent years, particularly during the pandemic. Unfortunately, high doses of...
FDA Medwatch Alert: FDA Updating Warnings to Improve Safe Use of Prescription Stimulants Used to Treat ADHD and Other Conditions
What safety concern is FDA announcing? To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, the U.S. Food and Drug Administration (FDA) is requiring...
FDA Approves Mydayis (mixed salts of a single-entity amphetamine product) – A New Once-Daily Option for ADHD
Lexington, Mass., USA – June 20, 2017 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved Mydayis (mixed salts of a single-entity amp...
FDA Medwatch Alert: Teva's Adderall 30 mg Tablets: Counterfeit Product - Contains Wrong Active Ingredients
ISSUE: FDA is warning consumers and health care professionals about a counterfeit version of Teva Pharmaceutical Industries' Adderall 30 milligram tablets that is being purchased on the Internet....
FDA Medwatch Alert: Adderall XR (amphetamine)
FDA issued a Public Health Advisory to notify healthcare professionals that Health Canada, the Canadian drug regulatory agency, has suspended the sale of Adderall XR in the Canadian market. Adderall...
FDA Medwatch Alert: Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder - Communication about an Ongoing Safety Review
Products involved include: Focalin, Focalin XR (dexmethylphenidate HCl ); Dexedrine, Dexedrine Spansules, Dextroamphetamine ER, Dextrostat (dextroamphetamine sulfate); Vyvanse (lisdexamfetamine...
Further information
Related condition support groups
Attention-Deficit Hyperactivity Disorder (ADHD), Narcolepsy